CAJ | 학술논문

目的：评价树突状细胞联合自体细胞因子诱导杀伤细胞（ DC/CIK）维持治疗晚期非小细胞肺癌（ NSCLC）的疗效和不良反应。方法根据治疗情况将2010年1月至2014年1月120例含铂方案化疗4～6个周期后疾病稳定的晚期NSCLC患者分为对照组（ n＝65）和研究组（ n＝55），仅研究组化疗后接受DC/CIK维持治疗。对两组进行生存随访并比较中位无进展生存期（ PFS）和总生存期（ OS），同时记录不良反应情况。结果研究组的中位PFS为5．0个月，高于对照组的3．5个月，差异有统计学意义（P＜0．05）；研究组的中位OS为8．5个月，与对照组（8．0个月）的差异无统计学意义（P＞0．05）；两组化疗后获不同疗效亚组中位PFS和OS的差异均无统计学意义（ P＞0．05）。常见不良反应为骨髓抑制、发热、乏力和关节酸痛，两组不良反应发生率的差异无统计学意义（ P＞0．05）。结论 DC/CIK维持治疗可延长化疗后疾病稳定晚期NSCLC患者的进展时间，且不良反应轻，患者可耐受。
목적：평개수돌상세포연합자체세포인자유도살상세포（ DC/CIK）유지치료만기비소세포폐암（ NSCLC）적료효화불량반응。방법근거치료정황장2010년1월지2014년1월120례함박방안화료4～6개주기후질병은정적만기NSCLC환자분위대조조（ n＝65）화연구조（ n＝55），부연구조화료후접수DC/CIK유지치료。대량조진행생존수방병비교중위무진전생존기（ PFS）화총생존기（ OS），동시기록불량반응정황。결과연구조적중위PFS위5．0개월，고우대조조적3．5개월，차이유통계학의의（P＜0．05）；연구조적중위OS위8．5개월，여대조조（8．0개월）적차이무통계학의의（P＞0．05）；량조화료후획불동료효아조중위PFS화OS적차이균무통계학의의（ P＞0．05）。상견불량반응위골수억제、발열、핍력화관절산통，량조불량반응발생솔적차이무통계학의의（ P＞0．05）。결론 DC/CIK유지치료가연장화료후질병은정만기NSCLC환자적진전시간，차불량반응경，환자가내수。
Objective To evaluate the toxicity and efficacy of dendritic cells/cytokine-induced killer cells ( DC/CIK) as the maintenance therapy for advanced non-small cell lung cancer ( NSCLC) . Methods During January 2010 and January 2014, 120 ad-vanced NSCLC patients in stable condition were enrolled after 4-6 cycles chemotherapy containing platinum. According to the treatment, patients were assigned into control group ( n=65) and study group ( n=55) . Only the study group received DC/CIK maintenance ther-apy. Both groups were followed up and the progression free survival ( PFS) and overall survival ( OS) were compared. Moreover, the adverse reaction was recorded. Results The median PFS and OS were 5. 0 and 8. 5 months in study group and 3. 5 and 8. 0 months in control group, respectively. The median PFS was higher in study group versus control group ( P<0. 05) . No significant differences were observed on median OS between both groups. In addition, there were similar median PFS and OS between different chemotherapeutic efficacy of sub-group. The common adverse reaction included myelosuppression, fever, fatigue and joint pain. The differences of both groups were not statistically significant ( P>0. 05) . Conclusion DC/CIK as the maintenance therapy can prolong the progression of advanced NSCLC patients in stable condition with tolerable and low adverse reaction.